ArticleJournal of translational medicine2017
High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.
Article in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Comparing machine learning methods predicting transcriptome from epigenome with applications to association studies.Genome biology · 2026Article
- SETD4 as a marker of disease burden and treatment response in childhood acute lymphoblastic leukemiaOncology letters · 2026Article
- Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG.Molecular biology reports · 2026Article
- Unveiling the link between arsenic toxicity and diabetes: an in silico exploration into the role of transcription factors.Toxicological research · 2024Article
- Establishment and verification of a TME prognosis scoring model based on the acute myeloid leukemia single-cell transcriptome.Scientific reports · 2024Article
- Refining epigenetic prediction of chronological and biological age.Genome medicine · 2023Article
- Reversal of Multidrug Resistance by Symmetrical Selenoesters in Colon Adenocarcinoma Cells.Pharmaceutics · 2023Article
- A novel scoring system for the quantitative prediction of prognosis in acute myeloid leukemia.Frontiers in oncology · 2023Article
- Identification ofFrontiers in cell and developmental biology · 2021Article
- Article
- Identification of an Immune-Related Gene Signature Based on Immunogenomic Landscape Analysis to Predict the Prognosis of Adult Acute Myeloid Leukemia Patients.Frontiers in oncology · 2020Article
- Molecular targeting in acute myeloid leukemia.Journal of translational medicine · 2017Review
- PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia.Journal of translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown.
methodsIn this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients.
resultsIn the first cohort, compared to low expression of ETS2 (ETS2
conclusionsOur results indicate that ETS2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.